Eagle’s Eye View: Smartwatch Screening Improved AFib Detection
In this week’s View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels in treating patients who have either heart failure (HF) or HF with preserved ejection fraction (HFpEF).
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Arrhythmias and Clinical EP, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Prevention, Stable Ischemic Heart Disease, Atherosclerotic Disease (CAD/PAD), Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Interventions and Coronary Artery Disease, Interventions and Imaging, Exercise, Chronic Angina, Acute Coronary Syndromes
Keywords: Percutaneous Coronary Intervention, Angina, Stable, Coronary Artery Disease, Wearable Electronic Devices, Atrial Fibrillation, Electrocardiography, Telemedicine, Photoplethysmography, Diabetes Mellitus, Kidney Diseases, Patient-Centered Care, Tomography, Optical Coherence, Decision Making, Exercise, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, EaglesEyeView
